Use of drug reduces likelihood of progression to multiple sclerosis
People who received injections of the multiple sclerosis (MS) drug interferon beta-1a soon after their first signs of possible MS were less likely to progress to clinically definite MS than people who switched to interferon beta-1a from placebo, according to new phase three results of the three-year REFLEXION clinical trial that will be presented as part of the Emerging Science program (formerly known as Late-Breaking Science) at the American Academy of Neurology's 64th Annual Meeting in New Orleans, April 21 to April 28, 2012.
The trial was conducted with the human serum albumin-free formulation of interferon beta-1a, which is now available in all European Union countries, Australia, Canada and Switzerland, as well as a number of countries in Asia, Latin America, Africa and the Middle East. It is not available in the United States.
"While we've known it's beneficial to start MS drugs as soon as possible, this is the first trial to show a benefit of early injections of interferon beta-1a treatment at three years," said Mark Freedman, MD, with the University of Ottawa in Ontario, Canada, and a Fellow of the American Academy of Neurology.
The three-year clinical trial involved 517 people who had experienced a first clinical episode suggestive of a demyelinating event, such as tingling, numbness, muscle weakness or problems with balance, along with having at least two clinically silent brain lesions detected by a brain MRI scan.
For two years, one-third of the participants received 44 mcg of interferon beta-1a subcutaneously three times a week; one-third received 44 mcg of the drug once a week, which is an unapproved dosage; and another one-third received placebo for two years or until experiencing a second clinical episode, at which point they were switched to three-times-weekly dosing. After the two years were over, the 133 people who were still receiving the placebo were switched to the three-times-weekly dose and the others continued their originally allocated dosages. The participants started their treatment an average of 58 days after their first symptoms.
After the third year of the study, the researchers found that those who had been receiving the drug three times a week or once a week for the duration of the trial were less likely to be diagnosed with clinically definite MS (defined as having a second clinical attack or a sustained increase in the Expanded Disability Status Scale disability score of greater than 1.5) than those who had initially received the placebo. The cumulative probability of being diagnosed with clinically definite MS by the end of the third year was 41 percent for the delayed treatment group (people who had switched from placebo to three-times-weekly treatment), 28 percent for those who had received once-a-week treatment all three years, and 27 percent for those who had three-times-weekly treatment for three years.
The study also found that those who had received the treatment for the full three years were less likely to meet the McDonald criteria for a MS diagnosis, a different measure than the one for clinically definite MS that includes an evaluation of MRI. A total of 87 percent of people who had switched from placebo to the treatment after two years met the McDonald criteria for MS after three years, compared with 79 percent of those who had received the weekly treatment and 67 percent of those who had treatments three times a week.
"While doses three times a week and once a week equally delayed a clinically definite MS diagnosis without MRI measures, there were significantly more benefits in taking the drug three times a week compared with once a week when it came to brain lesion changes and other McDonald criteria for diagnosing MS," said Freedman.
The REFLEXION trial is ongoing and will provide long-term data out to five years.
The most common adverse events in the trial were flu-like symptoms, injection site reactions and headache.
Provided by American Academy of Neurology
- Adding steroid drug to MS treatment may reduce disease activity Apr 30, 2009 | not rated yet | 0
- ONO-4641 pill reduced number of MS lesions in Phase II trial Apr 16, 2012 | not rated yet | 0
- Study revisits first clinical trial to treat multiple sclerosis decades later Apr 22, 2011 | not rated yet | 0
- Study finds twenty percent of children with MS don't respond to first-line treatment Jan 26, 2011 | not rated yet | 0
- If MRI shows signs of MS, will the disease develop? Dec 10, 2008 | not rated yet | 0
- Motion perception revisited: High Phi effect challenges established motion perception assumptions Apr 23, 2013 | 3 / 5 (2) | 2
- Anything you can do I can do better: Neuromolecular foundations of the superiority illusion (Update) Apr 02, 2013 | 4.5 / 5 (11) | 5
- The visual system as economist: Neural resource allocation in visual adaptation Mar 30, 2013 | 5 / 5 (2) | 9
- Separate lives: Neuronal and organismal lifespans decoupled Mar 27, 2013 | 4.9 / 5 (8) | 0
- Sizing things up: The evolutionary neurobiology of scale invariance Feb 28, 2013 | 4.8 / 5 (10) | 14
Indeterminism in Classical Physics
4 hours ago I was reading the Roger Penrose book Emperor's New Mind and he was explaining the determinism in Newtonian mechanics. He says that if we consider...
Current in two wires
4 hours ago Wire A and B, which have the same cross-sectional area are connected in series. There is a p.d. V across the whole wire. Suppose the two wires...
understanding the dipole model for Rayleigh scattering
6 hours ago Hello. I am currently studying scattering theory in detail for my BSc thesis, and I'm starting with Rayleigh scattering. I'm following Scattering...
question on coriolis effect with drag force
12 hours ago I really need help with this question. A small floating object initially moves with velocity v on the surface of a liquid at latitude λ. The...
Question of reflection and transmission of TEM wave in normal incidenc
18 hours ago Suppose TEM wave in +z normal to a boundary on xy plane at z=0. We know *E* & *H* are tangential to the boundary. Let ##\vec E_i=\hat x E##, be the...
the rudyak-krasnolutski effective potencial
19 hours ago Hi ... anyone now how to calculate or the formula of the rudyak-krasnolutski EFFECTIVE potencial ? the effective potencial includes the angular...
- More from Physics Forums - Classical Physics
More news stories
Little is known about why asthma develops, how it constricts the airway or why response to treatments varies between patients. Now, a team of researchers at Weill Cornell Medical College, Columbia University Medical Center ...
Inflammatory disorders 21 hours ago | not rated yet | 0 |
The negative effects of poorly controlled asthma symptoms on sleep quality and academic performance in urban schoolchildren has been confirmed in a new study.
Inflammatory disorders May 21, 2013 | not rated yet | 0
Patients with inflammatory bowel disease (IBD) are at higher risk of melanoma, a form of skin cancer, report researchers at Mayo Clinic. Researchers found that IBD is associated with a 37 percent greater risk for the disease. ...
Inflammatory disorders May 20, 2013 | 4.5 / 5 (2) | 0
(Medical Xpress)—Inflammation is an important response in the body - it helps you to kill off invaders such bacteria that could cause a harmful infection. But if it's chronic or uncontrolled, inflammation can also cause ...
Inflammatory disorders May 14, 2013 | 5 / 5 (1) | 0 |
An estimated 4,837,000 asthmatics with allergic bronchopulmonary aspergillosis (ABPA) could benefit substantially from antifungal treatment, say researchers from The University of Manchester and the University of Toronto.
Inflammatory disorders May 08, 2013 | not rated yet | 0
Saudi Arabia said Friday it would send samples taken from animals possibly infected with a deadly SARS-like virus to the United States for testing in a bid to find the source of disease.
1 hour ago | not rated yet | 0
(Medical Xpress)—A new study by researchers in the US has shown that an ancient virus can be modified to help in the fight against the simian immunodeficiency virus SIV, which is the equivalent in monkeys ...
1 hour ago | 5 / 5 (2) | 0 |
New research presented today shows that formation of new neurons in the hippocampus - a brain region known for its importance in learning and remembering - could cause forgetting of old memories by causing a reorganization ...
1 hour ago | not rated yet | 0
Ernie Pyle – an iconic war correspondent in World War II – reportedly said "There are no atheists in foxholes." A new joint study between two brothers at Cornell and Virginia Wesleyan found that only ...
1 hour ago | 3 / 5 (1) | 0
(Medical Xpress)—Regulating the distribution of power in neurons is done by a system that makes the national electric grid look simple by comparison. Each neuron has several thousand mitochondria confined ...
17 hours ago | 4.9 / 5 (7) | 0 |